IL2 and capillary leak syndrome: In particular, CLS has been reported as adverse effect of some monoclonal antibodies, including immunotherapy with human recombinant Interleukin-2 (IL-2), checkpoint inhibitors (anti-PD1) and rituximab (27, 29).